CRISPR-Enabled Nanocarrier Systems Against Multidrug-Resistant Bacteria: Emerging Potential of Bilosomes for Precision Antimicrobial Therapy

Objective(s): This review aims to evaluate the mechanistic convergence of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas genome-targeting technology with bile salt-stabilized vesicular nanocarriers (bilosomes) to circumvent physiological barriers and achieve sequence-specific eradication of multidrug-resistant (MDR) bacterial pathogens. Data sources: A systematic literature search was conducted across PubMed/MEDLINE, Web of Science, Scopus, ScienceDirect, and Google Scholar covering peer-reviewed studies published up to 2026. Study selection: Articles encompassing molecular mechanisms of antimicrobial resistance, CRISPR-Cas antimicrobials, non-viral nucleic acid delivery systems, and bilosomal formulations were critically scrutinized. Summary of contents of the article: Multidrug-resistant bacteria make regular antibiotics less effective and complicate clinical therapy. CRISPR-Cas technology can identify specific genomic loci and target resistance genes, virulence determinants, and plasmid scaffolds. However, therapeutic utilization is severely impeded by nuclease vulnerability, poor bacterial penetration, and transient stability. Bilosomes—lipid vesicles incorporated with deoxycholate, glycocholate, or taurocholate—exhibit superior membrane flexibility, resistance to gastrointestinal and enzymatic degradation, and enhanced cellular permeation compared to conventional liposomes. Functionalizing bilosomes with targeting ligands enables localized delivery and sustained release of Cas9 ribonucleoprotein complexes, driving sequence-specific chromosomal double-strand breaks, plasmid curing, and resensitization to conventional antibiotics. Conclusion: CRISPR-loaded bilosomal nanocarriers offer an effective non-antibiotic delivery platform capable of degrading bacterial chromosomes, curing high-risk resistance plasmids (blaKPC, blaNDM, mcr-1), and selectively reducing pathogen load without triggering broad microbiome dysbiosis. Keywords: Multidrug-resistant bacteria (MDR), CRISPR-Cas, Bilosomes, Nanocarrier delivery, Antimicrobial resistance (AMR), Plasmid curing, Precision antimicrobial therapy.

Authors

Publication Details

Journal
Journal of Drug Delivery and Therapeutics
Published
2026-11-15
DOI
https://doi.org/10.22270/jddt.v16i11.8085
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CRISPR-Enabled Nanocarrier Systems Against Multidrug-Resistant Bacteria: Emerging Potential of Bilosomes for Precision Antimicrobial Therapy

Shubhajit Sarkar, Bipasha De, Dipu Pan, Amit Mia et al.
Journal of Drug Delivery and Therapeutics
CRISPR and Genetic Engineering
article

CRISPR-Enabled Nanocarrier Systems Against Multidrug-Resistant Bacteria: Emerging Potential of Bilosomes for Precision Antimicrobial Therapy

Shubhajit Sarkar, Bipasha De, Dipu Pan, Amit Mia, Sagarika Ghosh, Sachin Biswas, Ratnaprava Das, Sudipta Mukherjee, Risha Saha, Soumita Guha
article en

Abstract

Objective(s): This review aims to evaluate the mechanistic convergence of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas genome-targeting technology with bile salt-stabilized vesicular nanocarriers (bilosomes) to circumvent physiological barriers and achieve sequence-specific eradication of multidrug-resistant (MDR) bacterial pathogens. Data sources: A systematic literature search was conducted across PubMed/MEDLINE, Web of Science, Scopus, ScienceDirect, and Google Scholar covering peer-reviewed studies published up to 2026. Study selection: Articles encompassing molecular mechanisms of antimicrobial resistance, CRISPR-Cas antimicrobials, non-viral nucleic acid delivery systems, and bilosomal formulations were critically scrutinized. Summary of contents of the article: Multidrug-resistant bacteria make regular antibiotics less effective and complicate clinical therapy. CRISPR-Cas technology can identify specific genomic loci and target resistance genes, virulence determinants, and plasmid scaffolds. However, therapeutic utilization is severely impeded by nuclease vulnerability, poor bacterial penetration, and transient stability. Bilosomes—lipid vesicles incorporated with deoxycholate, glycocholate, or taurocholate—exhibit superior membrane flexibility, resistance to gastrointestinal and enzymatic degradation, and enhanced cellular permeation compared to conventional liposomes. Functionalizing bilosomes with targeting ligands enables localized delivery and sustained release of Cas9 ribonucleoprotein complexes, driving sequence-specific chromosomal double-strand breaks, plasmid curing, and resensitization to conventional antibiotics. Conclusion: CRISPR-loaded bilosomal nanocarriers offer an effective non-antibiotic delivery platform capable of degrading bacterial chromosomes, curing high-risk resistance plasmids (blaKPC, blaNDM, mcr-1), and selectively reducing pathogen load without triggering broad microbiome dysbiosis. Keywords: Multidrug-resistant bacteria (MDR), CRISPR-Cas, Bilosomes, Nanocarrier delivery, Antimicrobial resistance (AMR), Plasmid curing, Precision antimicrobial therapy.

Journal of Drug Delivery and TherapeuticsVol. 16(11)
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon